Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15645 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Shanshan Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Cost-Benefit Analysis, Quality-Adjusted Life Years. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Research Fund for Clinical Pharmacy of China International Medical Foundation, National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To investigate the most matchable price of tirzepatide (TIRZ) compared with semaglutide (SEMA) in the treatment of type 2 diabetes in China.
Methods
The patient cohort and clinical efficacy data were derived from the SURPASS‐2 trial. Cost‐utility analysis and a binary search were performed to identify the most matchable price of TIRZ from a Chinese healthcare provider's perspective.
Results
After lifetime simulation, the quality‐adjusted life years of TIRZ 5, 10, 15 mg and SEMA 1 mg were 11.17, 11.21, 11.27 and 11.12 years, respectively. Despite an initial assumption that the annual cost of TIRZ equals that of SEMA, our analysis revealed that TIRZ is probably more cost‐effective than SEMA. A thorough evaluation of pricing showed that the cost ranges for TIRZ at doses of 5, 10 and 15 mg were $1628.61‐$1846.23, $1738.40‐$2140.95 and $1800.30‐$2430.81, respectively. After adjustment in the univariate sensitivity analysis, the cost ranges for TIRZ 5, 10 and 15 mg were $1542.68‐$1757.57, $1573.00‐$1967.16 and $1576.54‐$2133.96, respectively. These cost intervals were validated through robust probabilistic sensitivity analysis and scenario analysis, except for the cost range for TIRZ 5 mg.
Conclusions
This study shows that, using SEMA as a reference, the annual costs for TIRZ 10 and 15 mg are $1573.00‐$1967.16 and $1576.54‐$2133.96, respectively, for patients with type 2 diabetes in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Shanshan Hu, Chenyang Shi, Yuhang Ma, Guorong Fan
Förderung
- Research Fund for Clinical Pharmacy of China International Medical Foundation
- National Natural Science Foundation of China
Zitieren
APA
Hu, S., Shi, C., Ma, Y., Wang, S., Gu, S., Qi, C., & Fan, G. (2024). Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15645
Vancouver
Hu S, Shi C, Ma Y, Wang S, Gu S, Qi C, et al. Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15645
BibTeX
@article{Hu2024,
author = {Hu, Shanshan and Shi, Chenyang and Ma, Yuhang and Wang, Shuowen and Gu, Shengying and Qi, Chendong and Fan, Guorong},
title = {Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15645}
}
EUVIMED